A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
作者信息
Kudo Masatoshi
出版信息
Liver Cancer. 2017 Jun;6(3):177-184. doi: 10.1159/000462153. Epub 2017 Mar 9.
Abstract
摘要
相似文献
1
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.瑞戈非尼和乐伐替尼开启肝细胞癌系统治疗新时代。
Liver Cancer. 2017 Jun;6(3):177-184. doi: 10.1159/000462153. Epub 2017 Mar 9.
2
Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.在瑞戈非尼治疗期间怀疑发生间质性肺炎，并因随后使用乐伐替尼治疗不可切除肝细胞癌而加重。
Clin J Gastroenterol. 2019 Aug;12(4):355-360. doi: 10.1007/s12328-019-00983-x. Epub 2019 Apr 24.
3
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.分子靶向抗癌药物通过调节 MMP 和 TIMP 基因家族的表达抑制肝癌的侵袭和转移。
Biochem Biophys Res Commun. 2018 Oct 12;504(4):878-884. doi: 10.1016/j.bbrc.2018.08.203. Epub 2018 Sep 12.
4
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.瑞戈非尼作为晚期肝细胞癌二线治疗的作用及研究性治疗方案概况
J Hepatocell Carcinoma. 2016 Sep 21;3:31-36. doi: 10.2147/JHC.S112537. eCollection 2016.
5
CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma.CRISPR/Cas9全基因组筛选确定KEAP1为肝细胞癌中索拉非尼、乐伐替尼和瑞戈非尼的敏感性基因。
Oncotarget. 2019 Dec 17;10(66):7058-7070. doi: 10.18632/oncotarget.27361.
6
[New Systemic Therapies for Advanced Hepatocellular Carcinoma].[晚期肝细胞癌的新型全身治疗方法]
Korean J Gastroenterol. 2019 Jan 25;73(1):10-15. doi: 10.4166/kjg.2019.73.1.10.
8
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.晚期不可切除肝细胞癌患者的系统治疗：治疗方法的出现
J Gastrointest Cancer. 2018 Jun;49(2):107-115. doi: 10.1007/s12029-018-0065-8.
9
Novel approaches for molecular targeted therapy against hepatocellular carcinoma.针对肝细胞癌的分子靶向治疗新方法。
Hepatol Res. 2018 Jul;48(8):597-607. doi: 10.1111/hepr.13181. Epub 2018 May 17.
引用本文的文献
1
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities.肝细胞癌的靶向治疗：新旧机遇
Cancers (Basel). 2022 Aug 20;14(16):4028. doi: 10.3390/cancers14164028.
2
Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma.综合分析源于肝细胞癌的代谢途径活性亚型的预后特征。
Cancer Med. 2023 Jan;12(1):898-912. doi: 10.1002/cam4.4858. Epub 2022 Jun 1.
3
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.肝细胞癌的全身治疗：当前进展与展望
J Hepatocell Carcinoma. 2022 Mar 30;9:233-263. doi: 10.2147/JHC.S358082. eCollection 2022.
4
Genetic Landscape of Multistep Hepatocarcinogenesis.多步骤肝癌发生的遗传图谱
Cancers (Basel). 2022 Jan 23;14(3):568. doi: 10.3390/cancers14030568.
5
Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.仑伐替尼联合alisertib 通过靶向 DNA 损伤通路对肝癌的抗肿瘤作用。
Biomed Res Int. 2021 Jul 22;2021:6613439. doi: 10.1155/2021/6613439. eCollection 2021.
6
Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study.免疫检查点调节因子在胆管癌中的预后作用：一项初步研究。
J Clin Med. 2021 May 19;10(10):2191. doi: 10.3390/jcm10102191.
7
Altered Protein and Gene Expression of Beclin-1 Correlates with Poor Prognosis of Hcv-Associated Hepatocellular Carcinoma in Egyptian Patients.Beclin-1 的蛋白和基因表达改变与埃及 HCV 相关 HCC 患者的不良预后相关。
Asian Pac J Cancer Prev. 2021 Apr 1;22(4):1115-1122. doi: 10.31557/APJCP.2021.22.4.1115.
8
Therapy in Advanced Hepatocellular Carcinoma.晚期肝细胞癌的治疗
Semin Intervent Radiol. 2020 Dec;37(5):466-474. doi: 10.1055/s-0040-1719187. Epub 2020 Dec 11.
9
Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance.多价橡胶状 RNA 纳米颗粒用于靶向共递送紫杉醇和 miRNA 以沉默药物外排转运蛋白和肝癌耐药性。
J Control Release. 2021 Feb 10;330:173-184. doi: 10.1016/j.jconrel.2020.12.007. Epub 2020 Dec 13.
10
A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.一项随机、双盲、安慰剂对照、针对 MET 高表达肝细胞癌日本患者的 tivantinib 的 3 期研究。
Cancer Sci. 2020 Oct;111(10):3759-3769. doi: 10.1111/cas.14582. Epub 2020 Aug 26.
本文引用的文献
1
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
2
Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.瑞戈非尼作为二线全身治疗可能会改变肝细胞癌的治疗策略和管理模式。
Liver Cancer. 2016 Oct;5(4):235-244. doi: 10.1159/000449335. Epub 2016 Sep 14.
3
Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.中间期肝细胞癌患者改良分期系统——近畿标准的验证
Dig Dis. 2016;34(6):671-678. doi: 10.1159/000448834. Epub 2016 Oct 17.
4
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.乐伐替尼用于晚期肝细胞癌患者的2期研究。
J Gastroenterol. 2017 Apr;52(4):512-519. doi: 10.1007/s00535-016-1263-4. Epub 2016 Oct 4.
5
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan.日本173378例肝细胞癌患者的28年生存分析
Liver Cancer. 2016 Jul;5(3):190-7. doi: 10.1159/000367775. Epub 2016 May 10.
6
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma.索拉非尼在经动脉化疗栓塞术（TACE）难治性和中期肝细胞癌患者中的疗效
Liver Cancer. 2015 Dec;4(4):253-62. doi: 10.1159/000367743. Epub 2015 Oct 21.
7
Surgical and Locoregional Therapy of HCC: TACE.肝癌的手术及局部区域治疗：经动脉化疗栓塞术
Liver Cancer. 2015 Sep;4(3):165-75. doi: 10.1159/000367739. Epub 2015 Jul 10.
8
Locoregional Therapy for Hepatocellular Carcinoma.肝细胞癌的局部区域治疗
Liver Cancer. 2015 Sep;4(3):163-4. doi: 10.1159/000367741. Epub 2015 Jun 5.
9
Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).BCLC B期肝细胞癌的亚分类及治疗策略：改良博隆迪亚分类法（近畿标准）的提议
Dig Dis. 2015 Oct;33(6):751-8. doi: 10.1159/000439290. Epub 2015 Oct 21.
10
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.雷莫芦单抗二线治疗索拉非尼一线治疗后晚期肝细胞癌患者（REACH）：一项随机、双盲、多中心、III 期临床试验。
Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.
Zotero 插件